Crohn's Disease Clinical Trials in St Louis, Missouri

8 studies are recruiting for crohn's disease in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

    Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Specialists In Gastroenterology /ID# 283939, St Louis, Missouri
    Locations
    36 in total
    Run by
    AbbVie
  2. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

    The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

    Stage
    Phase 3
    Ages
    16 to 80
    Site
    Washington University School of Medicine ( Site 5058), St Louis, Missouri
    Locations
    499 in total
    Run by
    Merck Sharp & Dohme LLC
  3. A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

    The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual …

    Stage
    Phase 4
    Ages
    18 to 70
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    48 in total
    Run by
    Takeda
  4. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

    The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6…

    Stage
    Phase 3
    Ages
    18 to 70
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    183 in total
    Run by
    Eli Lilly and Company
  5. A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

    The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Contin…

    Stage
    Phase 3
    Ages
    2 to 19
    Site
    Washington University School of Medicine, St Louis, Missouri
    Locations
    68 in total
    Run by
    Eli Lilly and Company
  6. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

    Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Washington University /ID# 266938, St Louis, Missouri
    Locations
    255 in total
    Run by
    AbbVie
  7. A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

    This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-…

    Stage
    Phase 3
    Ages
    16 to 80
    Site
    Gateway Gastroenterology-Site Number: 8400097, St Louis, Missouri
    Locations
    35 in total
    Run by
    Sanofi
  8. A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

    This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Investigational Site Number: 8400013, St Louis, Missouri
    Locations
    66 in total
    Run by
    Sanofi

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.